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Lamins are major structural components of the lamina providing mechanical support for the nuclear envelope in vertebrates. A subgroup of
lamins, the A-type lamins, are only expressed in differentiated cells and serve important functions both at the nuclear envelope and in the
nucleoplasm in higher order chromatin organization and gene regulation. Mutations in A-type lamins cause a variety of diseases from muscular
dystrophy and lipodystrophy to systemic diseases such as premature ageing syndromes. The molecular basis of these diseases is still unknown.
Here we summarize known interactions of A-type lamins with components of the nuclear envelope and the nucleoplasm and discuss their potential
involvement in the etiology and molecular mechanisms of the diseases. Lamin binding partners involve chromatin proteins potentially involved in
higher order chromatin organization, transcriptional regulators controlling gene expression during cell cycle progression, differentiation and
senescence, and several enzymes involved in a multitude of functions.
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In eukaryotic cells the nucleus is surrounded by the nuclear
envelope (NE) that separates nuclear and cytoplasmic activities
[1,2]. The NE is composed of the inner (INM) and outer
(ONM) nuclear membrane, the nuclear pore complexes (NPCs)
and the nuclear lamina. The ONM is continuous with the
endoplasmic reticulum (ER) and covered with ribosomes, while
the INM has a unique protein composition. The INM and ONM
are separated by a luminal space, but are joined at sites
occupied by the NPCs that mediate bi-directional transport [3].
The lamina is a meshwork of lamins and lamin-binding proteins
underlying the INM [2,4–7]. Lamins also assemble into a
number of intranuclear structures such as foci, channels, or a
nucleoplasmic veil, and interact with a variety of intranuclear
proteins [8–11].
Lamins are type V intermediate filament proteins that have
a role in nuclear mechanics and structure, chromatin
organization, transcription, DNA replication, DNA damage
response and genome stability [2,12,13]. They contain a
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a basic structural unit they form coiled-coil dimers that
associate longitudinally to form head-to-tail polymers [14].
According to their primary sequence, biochemical properties
and expression patterns lamins have been classified as A- and
B-type lamins. Mammalian somatic cells express two major B-
type lamins, B1 and B2, which are products of different genes
(LMNB1 and LMNB2), and are essential for embryonic
development and viability of cells [15,16]. B-type lamins
contain a CAAX motif at the C-terminus that undergoes a
sequence of modifications, namely farnesylation of the
cysteine, proteolytic removal of AAX by Rce1, and carbox-
ylmethylation, favoring their association with nuclear mem-
branes throughout the cell cycle [17–19]. In contrast, all A-
type lamins are alternatively spliced products of one gene,
LMNA, and are widely expressed primarily in differentiated
cells. The best-characterized A-type lamins are A and C,
which are identical for the first 566 residues, but are distinct at
their carboxyterminal ends. Mature lamin A and lamin C have
unique C-terminal 98 and 6 residues, respectively. While lamin
C does not contain a CAAX motif, prelamin A undergoes
farnesylation, endoproteolytic processing by the zinc metallo-
protease Zmpste24 (and likely Rce1), and carboxylmethylation
at its CAAX motif, but is subsequently again proteolytically
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residues including the farnesyl moiety [17].
2. Lamin A/C complexes in human diseases
A-type lamins are dispensable during embryonic develop-
ment in mice, but fulfill essential roles in tissue homeostasis in
the adult organism as shown by targeted disruption of A-type
lamins in lamin A knock out mice and by expression of mutated
lamin A in knockin transgenic mouse models [20–26].
Mutations in LMNA cause a variety of human diseases termed
laminopathies (for reviews, see [13,17,27–29]). Several
laminopathies affect striated muscle (Emery–Dreifuss muscular
dystrophy/AD-EDMD, dilated cardiomyopathy/CMD1A, and
limb-girdle muscular dystrophy/LGMD1B), whereas others
primarily disrupt muscle and neurons (Charcot–Marie–Tooth
disorder/AR-CMT2B1), adipose tissue (familial partial lipody-
strophy/FPLD), or adipocytes and bone (mandibuloacral
dysplasia/MAD). Mutations in LMNA also cause a spectrum
of human progeroid syndromes affecting multiple tissues in
Hutchinson–Gilford Progeria Syndrome (HGPS), atypical
Werner's Syndrome (WS) and Restrictive Dermopathy (RD).
Most of these human diseases are autosomal dominant, while
the laminopathy mouse models require homozygous disruption
of A-type lamins to elicit a phenotype, except for the most
recent HGPS mouse models [25,26]. Interestingly, in humans
MAD and RD are also caused by mutations in Zmpste24, the
protease responsible for prelamin A processing [30–32]. Also,
mutations in the well-known A-type lamin binding partners
emerin, LAP2α and MAN1 have been implicated in X-linked
EDMD [33], dilated cardiomyopathy [34], and several disordersFig. 1. Schematic presentation of the intcharacterized by increased bone density (osteopoikilosis,
Buschke–Ollendorff syndrome and melorheostosis) [35],
respectively. Based on these findings it has been proposed
that A-type lamin complexes at the nuclear periphery and in
the nucleoplasm are required for multiple essential functions
in postnatal cells and for tissue organization and turnover.
Mutations in either lamins themselves or in lamin-binding
proteins may dominantly interfere with these functions and
cause the molecular and clinical phenotypes in laminopathy
patients [1]. Intriguingly, in around 60% of patients diagnosed
for EDMD, mutations were neither found in LMNA nor in
any of the disease-linked lamin-binding proteins [36],
suggesting that many more lamin binding or lamin-modifying
proteins than presently known can cause or contribute to
laminopathic diseases. Thus, the identification and functional
characterization of A-type lamin binding partners is a
prerequisite for understanding the molecular mechanisms of
laminopathies.
In the following chapters we focus on the formation of A-
type lamin networks (Fig. 1) through their interactions with
proteins at the nuclear membrane (Table 1) and in the nuclear
interior (Table 2) and discuss their potential role for A-type
lamin function in normal and diseased mammalian cells.
3. Membrane-associated A-type lamin complexes
3.1. A- and B-type lamin interactions
Although A- and B-type lamins colocalize at the nuclear
periphery [5,37,38], surprisingly little is known about the direct
interactions of these lamin subtypes. Direct homotypic anderaction network of A-type lamins.
Table 1




In vitro interaction In vivo interaction
B-type lamins Affinity chromatography, overlay assays with rat lamins A/C/B1 [39]; Yeast 2 hybrid interactions of human lamins A/B/C [42,45]
Column binding assays with bacterially expressed lamin A/C/B1/B2 [40,41]
Emerin Biomolecular interaction analysis of bacterially expressed lamin A and
emerin [189];
Co-Ip of lamin A/C with emerin from C2C12 cell and
hepatocyte lysates [191];
Blot overlays with bacterial emerin (mutants) and in vitro translated
lamin A [58];
Affinity chromatography and Co-Ip of muscle and liver lamin A with
bacterial emerin [190]
Yeast 2 hybrid interaction of emerin with lamin A/C [75,190]
Relocalization of emerin to the ER upon A-type lamin
deficiency [15,24,93,192]
MAN1 Microtiter and blot overlay assay using immobilized bacterial prelamin
A tail and in vitro translated MAN1 N-terminus [59]
LEM2 Blot overlay assays using bacterial lamin C tail and in vitro translated
LEM2 [54]
Relocalization of LEM2 to the ER upon A-type lamin
deficiency [54]
Nesprin-1 Blot overlay assay using immobilized bacterially expressed lamin A and
in vitro translated nesprin-1α (SR 5–7) [91]
Co-Ip of lamin A/C with Myne-1 from differentiated
C2C12 cell lysates [92]
A-type lamin-dependent relocalization of nesprin-1 [67,93]
Nesprin-2 Pulldown of lamin A/C with GST-nesprin-2 SR19-22 and nesprin-2
SR19-22 with GST-lamin C rod coil2 and tail from COS cells [67];
Direct yeast 2 hybrid interaction of nesprin-2 SR 19-22 and
lamin A [67];
Blot overlays with bacterial lamin A and nesprin-2 SR19-22 [67];
In vitro Co-Ip of in vitro translated lamin A with nesprin-2α and β [69]
Co-Ip of lamin A/C with nesprin-2 from vascular smooth
muscle cell lysates [69];
A-type lamin dependent relocalization of nesprin-2 [67,69]
SUN1, SUN2 Pulldown of in vitro translated lamin A/C with bacterially expressed
GST-SUN1/2 N-terminus [94];
A-type lamin-dependent relocalization of ectopic
SUN1/2 N-terminus [94];
In vitro Co-Ip of in vitro translated lamin A with SUN1 N-terminus [96] Yeast 2 hybrid interaction of SUN1 with lamin A tail [96];
Co-Ip of ectopic lamin A with SUN1 [96]
LAP1 Pulldown of native rat LAP1A/B with assembled native rat lamin A/C [106] Lamin A-dependent movement of LAP1C in heterokaryons [193];
Yeast 2 hybrid interaction between progerin and LAP1B [149]
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chromatography and solid-phase assays [39,40], and different
pairs of lamins were shown by chemical dissociation assays to
interact with different binding strengths [41]. Lamin A,
prelamin A, lamin B1, and lamin C also formed homo- and
heterodimers in yeast 2 hybrid assays [42]. However, the
relevance of these findings for the in vivo interactions of A- and
B-type lamins in higher eukaryotic cells is still unclear. There is
increasing evidence that A- and B-type lamins may predomi-
nantly form distinct homopolymers. They assemble in tempo-
rally and spatially different ways during NE reassembly after
mitosis [43–45] and form independent networks and complexes
in vivo [9,40,46–48]. Furthermore, in vivo a multitude of lamin-
binding proteins may regulate the formation of distinct lamin
complexes [37,49].
It is not clear whether disease-causing mutations interfere
with homo- or heterotypic lamin interactions and assembly.
Interestingly, 15 tested single amino acid exchanges in disease-
linked lamin A variants did not disrupt their interaction
properties as compared with wild type proteins in vitro [45],
suggesting that formation of lamin dimers may not be disturbed
in many laminopathies. Very recently, Debarre et al. showed by
fluorescence resonance energy transfer (FRET) analyses that
expression of a progeria linked lamin variant, which is a
farnesylated prelamin A with a 50 amino acid C-terminal
deletion, forms mixed homopolymers with A- and B-type
lamins, whereas A- and B-type lamins segregated into distinct
homopolymers in control cells [48]. This study is in agreement
with other observations showing accumulation of stableprogeria linked lamin variant (also called progerin) in the
nuclear lamina [50,51].
3.2. LEM domain protein complexes at the nuclear periphery
Several LEM (Lamina-associated polypeptide–Emerin–
MAN) domain containing proteins of the INM have been
identified as A-type lamin binding partners at the nuclear
periphery [2,7,52] (Fig. 2). The LEM domain is a ∼40 residue
structural motif that is shared by the founding members of the
LEM domain protein family, Lamina-associated polypeptide 2
isoforms, emerin and MAN1 [53] and other recently described
mammalian LEM proteins, such as LEM2 [54,55]. The LEM
motif mediates interaction with the DNA-crosslinking protein
barrier-to-autointegration factor (BAF) [43,56–60].
Emerin is a type II transmembrane protein of the INM with
an N-terminal LEMmotif and was found to interact with A-type
lamins by several in vitro and in vivo approaches (Table 1).
Mutations in the emerin gene cause X-linked EDMD with
slowly progressing skeletal muscle wasting, contractures of
tendons and cardiomyopathy [33]. Gene expression profiling of
muscle biopsies of EDMD patients with LMNA or emerin
mutations revealed a transcriptional fingerprint suggesting a
disruption of the retinoblastoma/Myo D pathways in muscle
regeneration [61]. In contrast, emerin knockout mice showed no
overt muscular dystrophy or cardiomyopathy, however, they
may have minimal motor and cardiac dysfunctions and an
impaired retinoblastoma/MyoD pathway affecting muscle
regeneration [62,63]. Fibroblasts derived from X-EDMD
Table 2




In vitro interaction In vivo interaction
DNA Gel overlay and filter binding assays using purified mammalian
lamin A/C and telomere/MAR DNA sequences [111,112,194];
EMSA and NMR using bacterial lamin A/C (Ig fold) and
DNA [113]
BAF Microtiter well binding assays using bacterially expressed
BAF and in vitro translated lamin A [74];
Blot overlay assays using bacterial prelamin A tail and in vitro
translated BAF [110]
histones Microtiter well binding assays using rat core histones and
bacterially expressed (non Ig fold) lamin C tail fragments [114]
LAP2α Blot overlay assays using in vitro translated, bacterially
expressed and purified lamin A/C and LAP2α [9]
Co-Ip of endogenous lamin A/C with LAP2α from HeLa, HDF and
SAOS-2 cell lysates [9,124];
A-type lamin-dependent relocalization of LAP2α [9]
pRb Isolation of lamin C in a human cDNA expression library screen
with bacterially expressed Rb [195];
Reciprocal GST pulldown and Co-Ip using bacterially expressed,
in vitro translated and baculoviral lamin A/C and Rb [128,129];
Pulldown of hypophosphorylated Rb with bacterial lamin C from
MOLT-4 cell lysates [128];
Blot overlays using in vitro translated lamin C and bacterially
expressed Rb [124]
A-type lamin dependent relocalization of Rb [124,133];
Reciprocal Co-Ip of Rb and lamin A/C from mouse embryonal
fibroblast and C2C12 lysates [85,196]
Mel18; UBC9;
hnRNP E1
Gel mobility shift assays using in vitro translated HGPS-specific
lamin A (progerin) and Mel-18, UBC9, hnRNP E1 [149]
Yeast 2 hybrid interaction of Mel18, UBC9, hnRNP E1 with
HGPS-specific lamin A (progerin) [149];
Co-Ip of lamin A/C (and progerin) with Mel18, UBC9,
hnRNP E1 from normal and progeria fibroblasts [149]
SREBP1 Pulldown of in vitro translated SREBP1 with GST/prelamin A
tail [160]
Yeast two hybrid interaction of mouse and human SREBP1 with
prelamin A tail [160];
Co-Ip of ectopic SREBP1 with ectopic lamin A from 293T cells [160];
Reciprocal Co-Ip of prelamin A and SREBP1 in
mevinolin-treated fibroblasts as well as MAD/ FPLD/ WS fibroblast
lysates [159]
c-Fos Pulldown of bacterial c-Fos (fragment) with GST-lamin A/C
fragments [161]
Yeast 2 hybrid interaction of lamins A/C with c-Fos bZIP [161];
A-type lamin dependent relocalization of c-Fos [161];
Co-Ip of c-Fos with lamin A/C from HeLa cells [161];
Interaction of lamin A with c-Fos by fluorescence resonance
energy transfer [161]
MOK2 Pulldown of ectopic MOK2 with a GST-lamin A/C rod
fragment from HeLa nuclear extracts [163]
Yeast 2 hybrid interaction of MOK2 and lamin C [163];
A-type lamin dependent relocalization of ectopic MOK2 [163]
actin Pulldown of actin with bacterially expressed lamin A tail from
HEp-2 and A549 cell lysates [174]
Co-Ip of actin with lamin A/C from differentiated C2C12 lysates [173];
Yeast 2 hybrid interaction of actin with lamin A tail [7]
12-LOX Yeast 2 hybrid interaction of 12-LOX and lamin A tail [197];
Reciprocal Co-Ip of lamin A and 12-LOX from A431 cell lysates [197]
PKC-α Overlay assay using bacterially expressed PKC-α on
2-dimensional blots of Swiss 3T3 cell nuclei [198];
Overlay assays using bacterially expressed PKC-α and
prelamin A fragments [181]
Narf Pulldown of in vitro translated, farnesylated prelamin A tail
with bacterially expressed GST-Narf [186]
Yeast 2 hybrid interaction of prelamin A tail and Narf [186]
Lco1 Overlay assays using bacterially expressed GST-lamin A/C
tail and in vitro translated Lco1 [187];
Pulldown of in vitro translated Lco1 with bacterially expressed
prelamin A tail [187];
Microtiter well binding assay using bacterial prelamin A
tail and in vitro translated Lco1 [187]
Yeast 2 hybrid interaction of lamin C and Lco1 [187];
A-type lamin dependent relocalization of ectopic Lco1 [187]
Viral E1B 19K Pulldown of in vitro translated E1B 19K by bacterially
expressed lamin A rod domain [184]
Yeast 2 hybrid interaction of E1B 19K with lamin A/C rod domain [184];
A-type lamin dependent relocalization of E1B 19K [184]
Titin Pulldown and microtiter assays using bacterial prelamin A
tail and in vitro translated titin C-terminus [188]
Yeast 2 hybrid interaction of titin C-terminus with lamin A/C Ig fold [188];
Co-Ip of lamin A/C with ectopic titin fragment from HeLa cells [188]
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Fig. 2. Schematic presentation of A-type lamin complexes with inner nuclear membrane (INM) proteins and with nucleoplasmic proteins and their potential role in
chromatin organization and gene regulation. For details, see text.
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have abnormally shaped nuclei with membrane and chromatin
protrusions [64,65]. Emerin may organize nuclear envelope
architecture through the reported interaction with various
structural proteins in the nucleus, including lamins, nesprins-1
and -2 and nuclear actin [66–69]. Emerin was also found to
promote actin polymerization and formation of a cortical actin
network beneath the NE [66]. However, in contrast to nuclei
of Lmna−/− mouse embryo fibroblasts, which have reduced
mechanical resistance [70–72], emerin-deficient mouse cells
showed normal nuclear stiffness and fragility, but an increased
nuclear shape variability and an altered mechanosensitive
gene regulation, leading to apoptosis in response to mechan-
ical stimulation [65]. The altered mechanosensitive gene
regulation and the deregulated Rb/MyoD pathway in emerin-
deficient cells suggest a role for emerin in gene regulation.
This hypothesis is further supported by the reported
interactions of emerin with transcriptional regulators, such
as BAF, Btf, GCL and YT521-B [58,73–75] and/or nuclear
actin and myosin I isoform [66,76] that in turn are implicated
in RNA polymerase II dependent transcription [77–80].
Furthermore, DNA microarray analysis of X-linked EDMD
patient cells revealed at least 28 upregulated genes in emerin
mutant cells [81].
MAN1 contains a nucleoplasmic N-terminal LEM domain,
two transmembrane segments in the INM and an intranuclear
C-terminal tail. The N-terminus of MAN1 interacts with the
lamin A tail and emerin in vitro [59] and is required for
targeting of MAN1 to the INM in vivo [82]. The C-terminusof MAN1 can physically interact with transcriptional regula-
tors, such as Btf and GCL [59], and with R-Smads, down-
stream components of the transforming growth factor-β
(TGFβ) signaling pathway [35,83,84]. The latter interaction
was found to antagonize TGFβ, activin and BMP signaling.
Fibroblasts from an osteopoikilosis patient with a loss-of-
function mutation in the MAN1 gene, and a human cell line,
in which MAN1 was downregulated by small interfering
RNAs showed increased expression of TGFβ-responsive
genes. The molecular mechanism of the MAN1-mediated
repression of the TGFβ pathways as well as its regulation is
not fully understood. Upon activation of the signaling
pathway, R-Smads are phosphorylated, heteromerize with
mediator Smads (Smad4) and are transported into the nucleus,
where they affect expression of target genes. MAN1 might
simply scavenge active Smads away from transcription
complexes to the NE, but may also affect phosphorylation,
oligomerization, and nuclear translocation of Smads. Since
Smad-MAN1 interaction occurred in a ligand independent
manner, and MAN1 is constitutively expressed in most cells,
MAN1 may serve as a permanent negative effector of the
pathway, ensuring a low basic signal in the absence of ligands.
One study reported reduced phosphorylation of R-Smads upon
overexpression of MAN1 [84]. Since MAN1 is located in the
nucleus, the phosphorylation defect may not be due to the
inhibition of kinases – located in the cytoplasm – but may
rather be caused by recruitment of protein phosphatases and
specific dephosphorylation of Smads at the NE. Intriguingly, a
recent report revealed association of lamin A/C with protein
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Rb protein upon TGFβ-induced growth arrest in Lmna−/−
mouse embryonic fibroblasts [85]. Thus, A-type lamin/MAN1/
PP2A complexes may be involved in signaling pathways
mediated by the TGFβ superfamily members, and mutations
in MAN1 and lamins may interfere with tissue-specific
signaling pathways and contribute to the pathogenesis in
laminopathic tissues.
LEM2 is a MAN1 related INM protein, forming an
evolutionary conserved family, expressed from yeast to man.
LEM2 binds to the C-terminus of lamin C in vitro and requires
A-type lamins for proper NE localization [54]. Interestingly,
overexpressed LEM2 formed clusters and membranous inva-
ginations at the NE as well as tubular structures interlinking
nuclei of adjacent cells, to which it recruits A-type lamins,
emerin and BAF, but not lamin B1 and the lamin B receptor
(LBR). This suggests a role of LEM2 in the specific
organization of A-type lamin, but not B-type lamin complexes
at the NE, and a function in nuclear architecture. LEM2 misses
a MAN1-specific RRM domain in the C-terminus, which has
been implicated in Smad binding in MAN1, and thus, does not
affect TGFβ signaling.
3.3. Non-LEM domain membrane proteins in lamin A/C
complexes
Nesprins comprise a recently discovered family of ubiqui-
tously expressed and evolutionary conserved proteins [86,87]
(Fig. 2). Through alternative transcription initiation, termina-
tion, and splicing three known nesprin genes give rise to many
protein isoforms with different reported names (Nesprin, Syne,
Myne, Enaptin, Nuance), of different sizes, and reported cellular
localizations at the INM, ONM, the nuclear interior and in
various cytoplasmic compartments. While Enaptin represents
the full length form of nesprin-1/syne-1/Myne1, Nuance is the
largest isoform of the nesprin-2/syne-2 family. These giant
isoforms of up to 1MD consist of an N-terminal calponin
homology-type actin binding domain, a central rod domain
containing spectrin repeats, and a conserved C-terminal KASH
(Klarsicht, Anc1 and Syne homology) domain with a
transmembrane region [88–90], and are proposed to integrate
the actin cytoskeleton with the nucleoskeleton. In contrast,
nesprin-3 may associate with the intermediate filament
cytoskeleton via plectin at the NE [87].
Some of the nesprin-1 and -2 isoforms have been shown to
directly interact with lamin A/C and emerin in vitro or require
lamin A expression for correct NE localization in vivo
[67,69,91–93]. Nesprins located in the ONM are anchored at
the NE through interaction of their KASH domain with SUN
domain proteins in the lumen [94,95]. The SUN domain
proteins SUN1 and SUN2 are located in the INM, interact with
A-type lamins [94,96], but their NE localization does not
depend on lamin A [94–96]. SUN and KASH domain proteins
thus may form a molecular link across the perinuclear space in
order to maintain the regular spacing between the INM and
ONM and to structurally bridge the nuclear interior with the
cytoskeleton. This bridging function is important for anchoringand positioning of the nucleus within the cells and for nuclear
migration [97,98].
Since various nesprin-1 and 2 isoforms are highly expressed
in heart and skeletal muscle [69,89,92] it is possible that
laminopathy-causing mutations in lamins interfere with the
bridging function of nesprin–lamin A/C–emerin complexes
contributing to the disease phenotypes; disease linked mutations
in nesprins themselves have not been reported yet. Lamin A/C–
nesprin complexes may also form scaffold structures regulating
the formation of signaling complexes involved in the main-
tenance and/or regeneration of muscle cells. Evidence for this
comes from reported binding of the nesprin-1α isoform to the
muscle A-kinase anchoring protein (mAKAP) [99]. mAKAP is
a scaffolding protein for signaling pathways at the NE of
differentiated myocytes involved in cardiac hypertrophy, such
as protein phosphatase 2A and the ryanodine receptor (RyR)
calcium release channel [100,101]. Furthermore, Syne-1, a
small nesprin-1 isoform, was originally identified as a binding
partner of MuSK, a receptor tyrosine kinase involved in
postsynaptic differentiation at the neuromuscular junction
[102]. Syne-1 is increased in central myonuclei that characterize
regenerating muscle, but transgenic mice overexpressing a
dominant negative C-terminal Syne (containing the KASH
domain) affected nuclear positioning but did not inhibit
neuromuscular junction formation [103].
The INM protein Lamina-associated polypeptide 1 (LAP1),
which exists as three developmentally regulated isoforms
LAP1A, B, and C [104,105] is another lamin A binding protein
[106], whose potential functions are just beginning to emerge
(Fig. 2). The luminal C-terminus of LAP1 binds to a dystonia-
causing mutated torsin A (DYT1) [107]. Torsin A is a member
of the AAA+ ATPase family and resides in the ER lumen, while
the mutated form DYT1 predominantly binds to the NE [108].
Thus, mutant torsin A may interfere with the functions of LAP1
or other NE proteins [109] raising the possibility that DYT1
dystonia shares molecular abnormalities with laminopathic
diseases.
4. Intranuclear A-type lamin networks
4.1. A-type lamin–chromatin complexes
A-type lamins bind to DNA, core histones and to the DNA
crosslinking protein BAF in several in vitro binding assays
[74,110–114] and might thus be involved in higher order
chromatin organization (Fig. 2), but the physiological sig-
nificance remains unclear. Nevertheless, a lipodystrophy-
causing R482W/Q missense mutation in lamin A reduced its
DNA binding, implying that changes in A-type lamin–
chromatin interactions may contribute to the cellular phenotype
in laminopathic disease [113].
BAF is a small, highly conserved chromatin protein that
binds lamin A in a phosphorylation-dependent manner
[74,110,115]. BAF itself binds DNA in a non-sequence-specific
manner by contacting the DNA phosphate backbone in the
minor groove [116,117]. It also binds histone H3 and some
linker histones [118]. Other BAF binding proteins, which may
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Like that can heterodimerize with BAF [119], and the LEM
domain protein LAP2α that can interact with BAF via its LEM
motif.
LAP2α is unique among the six known LAP2 isoforms as
it contains a specific C-terminus without a transmembrane
domain [120], localizes to the nucleoplasm in interphase
[121,122] and to telomeric chromosome regions in a
phosphorylation dependent manner during mitosis [43,123],
and specifically binds to nucleoplasmic A-type lamins in vitro
and in vivo [9,124]. The interaction of LAP2α with chromatin
is mediated by several ways: the LEM motif binding to BAF,
a LEM-like N-terminal domain interacting with DNA [56],
and the unique C-terminal chromosome interaction region that
is essential and sufficient for chromosome binding during
post-mitotic nuclear reassembly [122,125]. Thus, nucleoplas-
mic LAP2α–lamin A/C–BAF (Fig. 2) complexes are likely
involved in higher order chromatin organization during
mitotic nuclear assembly and in the interphase nucleus
[115,126]. However, fluorescence recovery after photobleach-
ing (FRAP) analyses of expressed GFP-tagged proteins
revealed that LAP2α and BAF are highly mobile in interphase
nuclei [43,44,127], suggesting that chromatin organization by
this complex may be highly dynamic in order to ensure
chromatin rearrangements and remodeling as well as epige-
netic control pathways during the cell cycle, senescence, and
differentiation.
4.2. A-type lamin interactions with LAP2α and Rb and related
complexes
LAP2α in conjunction with nucleoplasmic A-type lamins
has also been directly linked to cell cycle- and differentiation-
dependent gene regulation (Fig. 2). LAP2α and A-type
lamins bind the transcriptional regulator retinoblastoma
protein (Rb) in vitro and in vivo [85,124,128,129]. Rb
regulates progression through the cell cycle at the G1-S phase
transition by inhibiting the activity of cell cycle regulatory
E2F transcription factors in a phosphorylation-dependent
manner and by mediating epigenetic changes on the promoter
region of E2F/Rb target genes through recruitment of histone
deacetylases, SWI/SNF chromatin remodeling complex,
histone and DNA methyltransferases and polycomb group
protein complexes [130,131]. LAP2α was found to directly
associate with E2F/Rb promoter regions and to repress E2F
target genes during cell cycle progression in an Rb-mediated
manner [132], thereby favoring cell cycle exit and initiating
differentiation and/or senescence pathways. Consistent with a
proliferation-repressing function of LAP2α–lamin A/C com-
plexes Lmna−/− mouse cells showed increased cell prolifera-
tion and an inefficient TGFβ-mediated cell cycle arrest as a
consequence of decreased Rb stability or altered Rb
phosphorylation states [85,133]. The molecular mechanisms
how LAP2α may regulate Rb function are not yet clear but
may involve the control of Rb phosphorylation state,
recruitment of other regulatory proteins or targeting of Rb
to specific subdomains [1].In any case, Rb misregulation through mutated lamins or
LAP2α may be pivotal to the clinical manifestation of
laminopathies, since Rb is involved in key regulatory pathways
during myogenesis [134–136], adipogenesis [137,138], osteo-
genesis [139] and differentiation of epidermis [140], tissues that
are affected in laminopathies. In support of this hypothesis, the
lack of lamin A/C or expression of disease-linked mutated lamin
variants in myoblasts [141,142] or adipocytes [143] affect
differentiation. Interestingly, Rb has also been implicated in
DNA damage response and senescence, which is thought to
contribute to organismal ageing [144–146]. Since Rb is
downregulated in Zmpste24−/− mice, which lack correctly
processed lamin A and display progeria-type phenotypes [147],
defects in Rb pathways may also have a role in the etiology of
laminopathy-based premature aging syndromes.
A-type lamins have recently also been shown to interact
with the transcriptional repressor and tumor suppressor Mel-18
(Fig. 2), a member of the polycomb group proteins that are
involved in development, differentiation and self-renewal of
specific stem cell types [148,149]. Mel18 is a nuclear, DNA-
binding zinc finger protein [150,151] that negatively regulates
the self-renewal activity of hematopoietic stem cells [152], and
mice lacking Mel18 exhibit strong growth retardation, trans-
formation of the axial skeleton and immune defects [153,154].
Thus, defects in the interplay of LAP2α-lamin A/C complexes
with Rb and Mel-18 might have pleiotropic effects on gene
regulation during tissue differentiation and regeneration,
contributing to the broad spectrum of disease phenotypes.
4.3. Other gene regulatory lamin A complexes (Fig. 2)
The sterol regulatory element binding protein 1 (SREBP1) is
a member of the basic helix–loop–helix transcription factor
family and has a role in the upregulation of PPARγ in lipid
homeostasis and adipogenesis [155–157]. The SREBP1
precursor is embedded in the ER membrane and is proteoly-
tically cleaved upon activation to allow the transcriptionally
active N-terminus translocating to the nucleus [158]. SREBP1
preferentially interacts with the C-terminal tail of prelamin A
[159,160]. It is sequestered to the nuclear rim together with
upregulated prelamin A in 3T3 cells treated with the farnesyl
transferase inhibitor mevinolin, or in fibroblasts from lipody-
strophy-linked MAD, FPLD and WS patients. Furthermore,
FPLD-causing A-type lamin mutants bind less efficiently to
SREBP1 in vitro [160], and upregulated pre-lamin A reduced
expression of the SREBP1 downstream target PPARγ [159].
Altogether, these data suggest that altered prelamin A/SREBP1
interactions may affect gene regulatory proteins involved in
adipogenesis (e.g. PPARγ) and can thus be causative for
various lipodystrophic phenotypes in relevant laminopathies.
A-type lamins also interact in vitro and in vivo with c-Fos
[161], a member of the AP-1 transcription factor complex that
has important roles in cell proliferation and differentiation
[162]. Lamin A/C sequesters c-Fos to the NE and inhibits c-Fos/
c-Jun heterodimerization leading to decreased DNA-binding
and transcriptional activity of AP-1. This model is consistent
with the observed proliferation enhancement in Lmna−/−
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lamin A on the AP-1 function has not been tested yet.
The transcriptional regulator MOK2 interacts with A-type
lamins in vitro and in vivo [163]. It competes with retinal
degenerative disease associated cone-rod homeobox (Crx)
transcription factors for DNA binding and represses Crx target
gene expression. It is not known yet how lamin A/C may
influence this activity. Interestingly, the lamin A-binding
protein BAF (see above) is also involved in direct repression
of Crx-dependent gene expression by binding to Crx and other
homeodomain transcription activators [164]. Thus, lamin A/C–
BAF complexes may cooperatively regulate Crx-dependent
genes. MOK2 has also been reported to bind RNA and
ribonucleoprotein components [165], but the functional sig-
nificance of these findings in the context of lamin functions and
laminopathies remains unclear.
A-type lamins have also been reported to interact with
heterogeneous nuclear ribonucleoprotein E1 (hnRNP E1) [149].
hnRNP E1 binds C-rich telomeric DNA motifs [166] and
specific mRNAs via its KH domains and provides mRNA
stability and translational control by largely unknown mechan-
isms [167–170] In the context of laminopathies, it is interesting
to note that hnRNP E1 has been shown to stimulate collagen
expression post-transcriptionally by stabilizing its mRNA
[171]. While increased levels of hnRNP E1 and upregulation
of collagen synthesis have been reported in the heart of
cardiomyopathy patients leading to fibrosis [171], it remains to
be seen whether this is also detectable in lamin-linked
cardiomyopathies.
Besides the reported interactions of A-type lamins with
specific transcription factors and their potential involvement
in specific pathways, they may also affect overall gene
transcription on a more general scale based on the following
findings: RNA polymerase II (Pol II) activity, which is
responsible for the transcription of all mRNAs, is inhibited
by dominant negative lamin A mutants that destroy normal
lamin organization [172]. Furthermore, A-type lamins interact
with nuclear actin [7,173,174], which is an essential
component of Pol II preinitiation complexes [77] interacting
with the C-terminal domain of the largest subunit of Pol II
[78]. Actin has also been implicated in RNA polymerase I
and III dependent transcription and other nuclear activities,
such as chromatin remodeling and nucleocytoplasmic traf-
ficking [175,176]. This might indicate that A-type lamins
form a functional network with actin and possibly actin
-binding proteins emerin and nesprin (see above) in diverse
nuclear processes.
4.4. A-type lamin binding partners of diverse or unknown
function
In the past years, lamin A/C was found to bind to several
proteins with a wide range of functions and enzymatic activities:
The ubiquitin-conjugating enzyme E2I/UBC9 [149] med-
iates SUMO modification of proteins implicated in cell cycle
and transcriptional regulation, DNA repair and the maintenance
of genome integrity (reviewed in [177]). Interestingly, thecardiomyopathy-linked lamin C D192G variant disrupted
SUMO1 distribution patterns [178], suggesting that lamin
A/C complexes may be involved in the regulation of
posttranslational modifications of proteins and a variety of
cellular functions controlled by sumoylation.
Platelet 12-lipoxygenase (12-LOX) [179] metabolizes ara-
chidonic acid (AA) to 12-hydroperoxyeicosatetraenoic acid
(12-HPETE), which is subsequently converted to the lipid
mediator 12(S)-HETE [180] that induces a plethora of cellular
responses.
The serine-threonine kinase PKC-α [181] phosphorylates
a variety of protein targets in diverse cellular activities and
transformation (reviewed in [182]). Lamin A binds to the
N-terminal regulatory domain of PKC, implicating a role of
lamins in controlling PKC-α kinase activity.
Adenoviral protein E1B 19K [183,184] involved in anti-
apoptotic signaling upon adenoviral transfection functions and
localizes to the nucleus in an A-type lamin dependent manner.
Although adenoviruses are known to be cardiotrophic and may
thus contribute to cardiomyopathy [185], a direct correlation
between adenoviral infection and laminopathic disease has not
been reported yet.
The nuclear prelamin A recognition factor (Narf) [186] and
Lamin companion 1 (Lco1) [187] have been shown to interact
with A-type lamins, but due to lack of antibodies or low
expression levels, localization of endogenous Narf and Lco1
has not yet been shown.
Titin was recently identified as a novel A-type lamin binding
partner [188], but the role of nuclear-specific titin isoforms in
chromatin and nucleoskeletal organization remains to be further
investigated in mammalian cells.
5. Concluding remarks
The past years have seen publications of a huge amount of
reports on new binding partners that may simultaneously or
competitively interact with A-type lamins in a spatially and
temporally regulated manner. These complex lamin interac-
tion networks suggest the involvement of A-type lamins in a
plethora of functions spanning from mere structural support
and protection from mechanical stress over formation of
platforms for signaling cascades to direct control of signaling
molecules and transcription factors. A direct link of most of
these interactions and potential functions of lamins to the
etiology and cellular and tissue-specific pathologies in
laminopathy patients is less clear. It will be a major challenge
in the coming years to investigate the in vivo relevance of the
reported interactions in suitable cellular and animal models
in order to evaluate the potential involvement in disease
mechanisms.
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